In addition to APPA’s applicability in OA, there is an increasing view that inflammation, in particular driven via NFkB, plays a pivotal role in the development of Alzheimer ’s disease (AD). AKLRD is planning to explore the use of APPA as an anti-inflammatory treatment for AD, driven by reported improvements in cognition in a handful of AD patients taking APPA for OA. An eminent clinical AD expert believes that APPA is a suitable candidate for a Phase II 18-month AD study. Following a science advice meeting, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has also indicated support.
Ongoing research into the anti-inflammatory mode of action of APPA has shown APPA could be a viable candidate in a subset of rheumatoid arthritis patients, a market where pricing is attractive.